JP2019533008A - ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法 - Google Patents

４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法 Download PDF

Info

Publication number
JP2019533008A
JP2019533008A JP2019535991A JP2019535991A JP2019533008A JP 2019533008 A JP2019533008 A JP 2019533008A JP 2019535991 A JP2019535991 A JP 2019535991A JP 2019535991 A JP2019535991 A JP 2019535991A JP 2019533008 A JP2019533008 A JP 2019533008A
Authority
JP
Japan
Prior art keywords
composition
weight
crystals
liquid
oltipraz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019535991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533008A5 (OSRAM
Inventor
クリス ガーランド アンソニー
クリス ガーランド アンソニー
アンネ ボルマン‐ケネディー バーバラ‐ジーン
アンネ ボルマン‐ケネディー バーバラ‐ジーン
フラムロゼ ボミ
フラムロゼ ボミ
ブレットバーナー
バーナー ブレット
エドワード グラス マイケル
エドワード グラス マイケル
キース ジャガー ケイシー
キース ジャガー ケイシー
ジェイ ブルーム コーリー
ジェイ ブルーム コーリー
ジョセフ カスタンティン マーク
ジョセフ カスタンティン マーク
バシュラール ロマン
バシュラール ロマン
Original Assignee
エスティー アイピー ホールディング エージー
エスティー アイピー ホールディング エージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスティー アイピー ホールディング エージー, エスティー アイピー ホールディング エージー filed Critical エスティー アイピー ホールディング エージー
Priority claimed from PCT/IB2017/001231 external-priority patent/WO2018047002A1/en
Publication of JP2019533008A publication Critical patent/JP2019533008A/ja
Publication of JP2019533008A5 publication Critical patent/JP2019533008A5/ja
Priority to JP2023077049A priority Critical patent/JP2023113634A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2019535991A 2016-09-12 2017-09-12 ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法 Pending JP2019533008A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077049A JP2023113634A (ja) 2016-09-12 2023-05-09 ４－メチル－５－（ピラジン－２－イル）－３ｈ－１，２－ジチオール－３－チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN201611031046 2016-09-12
IN201611031045 2016-09-12
IN201611031046 2016-09-12
IN201611031045 2016-09-12
US201662412701P 2016-10-25 2016-10-25
US62/412,701 2016-10-25
PCT/IB2017/001231 WO2018047002A1 (en) 2016-09-12 2017-09-12 Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077049A Division JP2023113634A (ja) 2016-09-12 2023-05-09 ４－メチル－５－（ピラジン－２－イル）－３ｈ－１，２－ジチオール－３－チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Publications (2)

Publication Number Publication Date
JP2019533008A true JP2019533008A (ja) 2019-11-14
JP2019533008A5 JP2019533008A5 (OSRAM) 2020-11-05

Family

ID=60569946

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019535991A Pending JP2019533008A (ja) 2016-09-12 2017-09-12 ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法
JP2023077049A Pending JP2023113634A (ja) 2016-09-12 2023-05-09 ４－メチル－５－（ピラジン－２－イル）－３ｈ－１，２－ジチオール－３－チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077049A Pending JP2023113634A (ja) 2016-09-12 2023-05-09 ４－メチル－５－（ピラジン－２－イル）－３ｈ－１，２－ジチオール－３－チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法

Country Status (9)

Country Link
US (2) US11185544B2 (OSRAM)
EP (1) EP3509641A1 (OSRAM)
JP (2) JP2019533008A (OSRAM)
KR (1) KR20190089851A (OSRAM)
CN (1) CN109996563A (OSRAM)
AU (1) AU2017322544B2 (OSRAM)
BR (1) BR112019004639A2 (OSRAM)
CA (1) CA3036630A1 (OSRAM)
PH (1) PH12019500530A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531344A (ja) * 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260604B2 (en) * 2018-03-14 2022-03-01 Andrew Reynolds Method and system for dispensing molten wax into molds by means of a desktop apparatus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515453A (ja) * 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
KR20050014960A (ko) * 2003-08-01 2005-02-21 씨제이 주식회사 Ｂ형 간염 치료 및 간 조직 재생용 약제학적 조성물
JP2006511508A (ja) * 2002-11-26 2006-04-06 シージェー コーポレーション オルチプラズの製造方法
JP2007519714A (ja) * 2004-01-27 2007-07-19 シージェイ コーポレーション 低結晶性を有するか、または無定形化されたオルティプラッツの製造方法
JP2008521812A (ja) * 2004-11-24 2008-06-26 メドポイント ヘルスケア インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
JP2018520134A (ja) * 2015-06-25 2018-07-26 エステー イーペー ホールディング アーゲーＳＴ ＩＰ Ｈｏｌｄｉｎｇ ＡＧ オルチプラズを調製する方法
JP2019531344A (ja) * 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US7012148B2 (en) 2001-09-25 2006-03-14 Trustees Of Dartmouth College Compositions and methods for thionation during chemical synthesis reactions
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
US20050182128A1 (en) 2002-02-13 2005-08-18 Stephen Lam Use of anethole dithiolethione in lung cancer chemoprevention
DE602004005617T2 (de) 2003-12-22 2007-12-13 Alcon Inc. Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
FR2879444B1 (fr) 2004-12-22 2007-05-18 Oreal Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie
US20070036733A1 (en) 2005-08-12 2007-02-15 Takasago International Corp. (Usa) Sensation masking composition
WO2007019719A1 (en) 2005-08-15 2007-02-22 Givaudan Sa Cooling compounds
US7803353B2 (en) 2006-03-29 2010-09-28 The Procter & Gamble Company Oral care compositions having improved consumer aesthetics and taste
GB0704718D0 (en) 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
ATE540667T1 (de) 2007-06-13 2012-01-15 Givaudan Sa Verbindungen mit kühlender wirkung
WO2009014624A2 (en) 2007-07-20 2009-01-29 Johns Hopkins University Nrf2 inducers for treating epidermolysis bullosa simplex
US20090196907A1 (en) 2008-01-31 2009-08-06 Bunick Frank J Edible film-strips for immediate release of active ingredients
US8858995B2 (en) 2008-03-10 2014-10-14 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
AU2009223653B2 (en) 2008-03-10 2014-07-31 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
KR101057485B1 (ko) 2008-08-04 2011-08-17 서울대학교산학협력단 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물
WO2010128026A2 (en) 2009-05-05 2010-11-11 Givaudan Sa Organic compounds
EP2717860A4 (en) * 2011-06-08 2014-11-05 Sti Pharma Llc FORMULATION FROM A WATER SOLUBLE AND PHARMACEUTICALLY ACTIVE ORGANIC COMPOUND WITH CONTROLLED ABSORPTION FOR ONLY DAILY APPLICATION
US9012642B2 (en) * 2011-09-22 2015-04-21 Viiv Healthcare Uk Limited Pyrrolopyridinone compounds and methods for treating HIV
CN105007898A (zh) 2012-12-19 2015-10-28 卡希夫制药有限责任公司 难溶性药物的过饱和的稳定纳米颗粒
WO2015023889A1 (en) 2013-08-16 2015-02-19 Luminus Biosciences Inc. Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease
EP3110510A1 (en) 2014-02-27 2017-01-04 The Procter & Gamble Company Oral care compositions with a reduced bitter taste perception
WO2016207914A2 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for preparing oltipraz
ITUB20159655A1 (it) 2015-12-23 2017-06-23 Bormioli Rocco Spa Capsula di sicurezza di un contenitore.
ITUA20162141A1 (it) 2016-03-31 2017-10-01 Bormioli Pharma Spa Capsula di chiusura
KR20180123796A (ko) 2017-05-10 2018-11-20 서울대학교산학협력단 Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004515453A (ja) * 2000-05-05 2004-05-27 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション 癌を化学療法および放射線療法に付する間に細胞を保護するための組成物および方法
JP2006511508A (ja) * 2002-11-26 2006-04-06 シージェー コーポレーション オルチプラズの製造方法
KR20050014960A (ko) * 2003-08-01 2005-02-21 씨제이 주식회사 Ｂ형 간염 치료 및 간 조직 재생용 약제학적 조성물
JP2007519714A (ja) * 2004-01-27 2007-07-19 シージェイ コーポレーション 低結晶性を有するか、または無定形化されたオルティプラッツの製造方法
JP2008521812A (ja) * 2004-11-24 2008-06-26 メドポイント ヘルスケア インコーポレイテッド アゼラスチンを含む組成物およびその使用方法
JP2018520134A (ja) * 2015-06-25 2018-07-26 エステー イーペー ホールディング アーゲーＳＴ ＩＰ Ｈｏｌｄｉｎｇ ＡＧ オルチプラズを調製する方法
JP2019531344A (ja) * 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARMACOLOGYONLINE, vol. 2, JPN6021025232, 2010, pages 39 - 44, ISSN: 0004773500 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019531344A (ja) * 2016-09-12 2019-10-31 エスティー アイピー ホールディング エージー ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法

Also Published As

Publication number Publication date
US20220296589A1 (en) 2022-09-22
AU2017322544A1 (en) 2019-05-02
US20190209557A1 (en) 2019-07-11
US11185544B2 (en) 2021-11-30
AU2017322544B2 (en) 2022-06-02
BR112019004639A2 (pt) 2019-07-16
CA3036630A1 (en) 2018-03-15
JP2023113634A (ja) 2023-08-16
EP3509641A1 (en) 2019-07-17
PH12019500530A1 (en) 2020-02-24
KR20190089851A (ko) 2019-07-31
CN109996563A (zh) 2019-07-09

Similar Documents

Publication Publication Date Title
US20210052580A1 (en) Combination Compositions and Therapies Comprising 4-Methyl-5-(Pyrazin-2-yl)-3H-1,2-Dithiole-3-Thione, and Methods of Making and Using Same
EP3355869B1 (fr) Composition nettoyante auto-moussante à rincer, contenant de l'ivermectine
US20140147504A1 (en) Tetracycline topical formulations, preparation and uses thereof
WO2018047013A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
US10251891B2 (en) Aprepitant oral liquid formulations
JP2023113634A (ja) ４－メチル－５－（ピラジン－２－イル）－３ｈ－１，２－ジチオール－３－チオンの処方物、味覚修飾処方物、ならびにそれらの製造方法及び使用方法
WO2018047002A1 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
KR20060003009A (ko) 약학적 코 제형물 및 이의 이용 방법
KR102902972B1 (ko) Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
US11426403B2 (en) Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same
US9326977B2 (en) Anti-inflammatory compounds
EP3662891A2 (en) Composition for preventing hair loss or promoting hair growth
JP6765299B2 (ja) 水性製剤
EP4112037A1 (en) Oxygen gas sustained released nano-emulsion composition and method for producing the same
JPWO2017029710A1 (ja) ＮＳＡＩＤｓまたはヘパリン類含有口腔用組成物
US11135220B1 (en) Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
JP2018188377A (ja) 医薬組成物
KR101847720B1 (ko) 자초추출물을 함유하는 조성물
JP7214331B2 (ja) 医薬組成物
KR102240742B1 (ko) 크기가 조절된 나노에멀전 조성물 및 이의 제조 방법
JP2004155664A (ja) 皮膚機能改善剤
JP2021004267A (ja) 医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110